Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -9 of 9 Show results per page	View Search Criteria \| Help With Results

Last Modified: 12/28/2006 First Published: 11/1/1997


1.		Phase I/II Study of Samarium 153 and Autologous Bone Marrow Transplantation in Women With Stage IV Breast Cancer (Summary Last Modified 04/2002)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				21-65				Other				LSU-97447 NCI-V97-1341, NCT00003086

Last Modified: 9/11/2008 First Published: 5/21/2007


2.		Phase I/II Pilot Study of Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Closed				18 and over				Other				MAYO-MC0585 MAYO-IRB-1586-05, MC0585, NCT00478075

Last Modified: 11/12/2007 First Published: 5/23/2007


3.		Phase I/II Pilot Study of Samarium Sm 153 Lexidronam Pentasodium in Combination With Zoledronic Acid or Pamidronate Disodium in Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Supportive care, Treatment				Closed				18 and over				NCI				MAYO-MC048B MAYO-IRB-261-05, MC048B, NCT00482378

Last Modified: 5/5/2008 First Published: 1/14/2008


4.		Phase I/II Study of Conditioning Regimen Comprising Samarium Sm 153 Lexidronam Pentasodium and High-Dose Melphalan in Patients With Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				Other				MAYO-MC9981 MC9981, NCT00602706

Last Modified: 6/1/1998 First Published: 10/1/1997


5.		Phase II Study of Samarium Sm 153 Lexidronam Pentasodium (153Sm-lexidronam) in Combination with Total Androgen Blockade in Patients with Stage D2 Prostate Carcinoma (Summary Last Modified 06/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				CYTOGEN-424Sm17 NCI-V97-1255

Last Modified: 12/15/2008 First Published: 10/21/2005


6.		Phase II Study of High-Dose Samarium Sm 153 Lexidronam Pentasodium and Autologous Peripheral Blood Stem Cell Transplantation Followed By External-Beam Radiotherapy in Patients With Recurrent or Refractory, Metastatic, or Unresectable Osteosarcoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				13 to 50				NCI				JHOC-J0347 JHOC-03090802, NCT00245011

Last Modified: 7/1/1997


7.		Phase I Study of 153Sm-EDTMP in Children with Refractory Malignancies and Painful Osseous Lesions (Summary Last Modified 07/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Supportive care, Treatment				Completed				over 5 to 25				NCI				NCI-95-C-0113A

Last Modified: 12/3/2007 First Published: 4/14/2006


8.		Phase I Study of Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 and over				Pharmaceutical / Industry				ONCOTHER-20051780 ONCOTHER-424Sm35, CYTOGEN-ONCOTHER-20051780, NCT00316940


9.		Study of Docetaxel +153 Sm-EDTMP in Patients With Hormone-Refractory Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 to 80				Other				J0467 04-09-03-03, NCT00559429

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute